Skip to main content
SpringerLink
Log in

Efficacy and Safety of Etanercept in Psoriasis/Psoriatic Arthritis

An Updated Review

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

The introduction in recent years of biologic medicines has greatly changed the treatment of psoriasis and psoriatic arthropathy (PsA). These drugs have been effective in the treatment of these chronic, physically weakening disorders, offering good efficacy and a safety profile that differs from those of all other systemic therapies and medications available to date.

Different studies have assessed the efficacy and safety of etanercept in the treatment of psoriasis and PsA. Etanercept therapy for up to 144 weeks in psoriasis has shown maintenance of efficacy over time, recapture of initial clinical responses in patients who interrupted their etanercept therapy and were re-treated, an increased percentage of clinical responses in medium-dose non-responding patients who switched to higher dosages, good responses on quality-of-life tests, and an adverse event-adjusted rate similar to placebo. In PsA, etanercept therapy for up to 96 weeks was associated with inhibition of radiologic progression of the disease in addition to maintenance of efficacy over time and good responses on quality-of-life tests.

In studies of patients with psoriasis, the adverse effects of etanercept were mostly mild, did not require discontinuation of treatment, and were not associated with cumulative toxicity over time. However, safety concerns about etanercept therapy are well known, and include injection-site reactions, infections, congestive heart failure, demyelinating diseases, lupus-like syndromes, and neoplasms. There are no data about any new safety concerns when etanercept is combined with systemic traditional therapies, although use of this therapy has been reported in only a small number of patients to date.

Non-neutralizing anti-etanercept antibodies are not related to a decreased response to therapy and neutralizing antibodies have not been described to date. Treatment of patients infected with hepatitis C virus or HIV does not increase viral load in either case, affect liver function tests, or increase the risk of infections.

To date, the available data suggest that use of etanercept during pregnancy or in breast-feeding women should be avoided. Children and the elderly may be treated with similar efficacy and safety profiles as have been observed in adults. Non-live vaccines can be administered to patients taking etanercept.

Because of its long-term efficacy and safety, etanercept is likely to become a treatment option for consideration in the long-term management of patients with psoriasis and PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Table III

Similar content being viewed by others

References

  1. Gelfand JM, Weinstein R, Porter SB. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005 Dec; 141 (12): 1537–41

    Article  PubMed  Google Scholar 

  2. Lebowhl M. Psoriasis. Lancet 2003 Apr 5; 361 (9364): 1197–204

    Article  Google Scholar 

  3. Nash P, Clegg CO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005 Mar; 64 Suppl. 2: ii74–7

    Google Scholar 

  4. Leonardi CL, Powers JL, Matheson RT. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 Nov 20; 349 (21): 2014–22

    Article  PubMed  CAS  Google Scholar 

  5. Gottlieb AB, Matheson RT, Lowe N. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139 (12): 1627–32

    Article  PubMed  CAS  Google Scholar 

  6. Papp KA, Tyring S, Lahfa M. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 Jun; 152 (6): 1304–12

    Article  PubMed  CAS  Google Scholar 

  7. Mease PJ, Goffe BS, Metz J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 Jul 29; 356 (9227): 385–90

    Article  PubMed  CAS  Google Scholar 

  8. Mease PJ, Goffe BS, Metz J. Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis [poster]. European League Against Rheumatism (EULAR)/European Congress of Rheumatology; 2001 Jun 13-16; Prague

    Google Scholar 

  9. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62 (17): 2493–537

    Article  PubMed  CAS  Google Scholar 

  10. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999 Apr; 38 (4): 241–51

    Article  PubMed  CAS  Google Scholar 

  11. Malaviya R, Sun Y, Tan JK. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006 Oct; 55 (4): 590–7

    Article  PubMed  Google Scholar 

  12. Partsch G, Steiner G, Leeb BF. Highly increased levels of tumor necrosis factor-alfa and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518–23

    PubMed  CAS  Google Scholar 

  13. Brennan FM, Chantry D, Jackson A. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989 Jul 29; 2 (8657): 244–7

    Article  PubMed  CAS  Google Scholar 

  14. Braun J, Sieper J. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. Biodrugs 2003; 17 (3): 187–99

    Article  PubMed  CAS  Google Scholar 

  15. Feldman SR, Kimball AB, Krueger GG. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005 Nov; 53 (5): 887–9

    Article  PubMed  Google Scholar 

  16. Krueger GG, Langley RG, Finlay AY. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005 Dec; 153 (6): 1192–9

    Article  PubMed  CAS  Google Scholar 

  17. Moore A, Gordon KB, Kang S. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 Apr; 56 (4): 598–603

    Article  PubMed  Google Scholar 

  18. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006 Jun; 298 (1): 7–15

    Article  PubMed  CAS  Google Scholar 

  19. Krueger GG, Elewski B, Papp K. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): 112–9

    Article  Google Scholar 

  20. Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005; 6 (2): 121–36

    Article  PubMed  Google Scholar 

  21. Elewski B, Strober B, Tyring S. Etanercept 50mg once weekly sustains safety and efficacy for up to 96 weeks in plaque psoriasis patients [poster]. 15th Congress of the European Academy of Dermatology and Venereology; 2006 Oct 4-8; Rhodes

    Google Scholar 

  22. Elewski B, Leonardi C, Gottlieb AB. Etanercept dose escalation to 50mg twice weekly sustains safety and efficacy for up to 48 weeks in psoriasis patients who had incomplete response to 50mg once weekly [poster]. 15th Congress of the European Academy of Dermatology and Venereology; 2006 Oct 4-8; Rhodes

    Google Scholar 

  23. Elewski B, Leonardi C, Gottlieb AB. Sustained long-term clinical efficacy and safety for up to 2.5 years of etanercept in patients with psoriasis [poster]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

    Google Scholar 

  24. Griffiths CEM, Papp K, Koo J. Long-term patient-reported outcomes: etanercept therapy in patients with psoriasis [poster]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

    Google Scholar 

  25. Elewski B, Leonardi C, van de Kerkhof P. Evaluation of clinical efficacy of etanercept at two different dosages with and without dose interruption in patients with moderate to severe plaque psoriasis [poster]. t15th Congress of the European Academy of Dermatology and Venereology; 2006 Oct 4-8; Rhodes

    Google Scholar 

  26. Elewski B, Leonardi C, van de Kerkhof P. Evaluation of clinical response in psoriasis patients with an interruption of etanercept treatment [poster]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

    Google Scholar 

  27. Tyring S, Poulin Y, Langley R. A 96-week phase 3 study of safety and efficacy of etanercept 50mg twice weekly in patients with psoriasis [poster]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

    Google Scholar 

  28. Tyring S, Poulin Y, Langley RG. Safety and efficacy profiles of etanercept for up to 144 weeks in patients with moderate to severe plaque psoriasis [poster]. 65th Annual Meeting of the American Academy of Dermatology; 2007 Feb 2-6; Washington, DC

    Google Scholar 

  29. Felson DT, Anderson JJ, Boers M. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35

    Article  PubMed  CAS  Google Scholar 

  30. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): 116–21

    Google Scholar 

  31. Mease PJ, Kivitz AJ, Burch FX. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 Jul; 50 (7): 2264–72

    Article  PubMed  CAS  Google Scholar 

  32. Mease PJ, Kivitz AJ, Burch FX. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33 (4): 712–21

    PubMed  CAS  Google Scholar 

  33. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years [letter]. Clin Exp Rheumatol 2002; 20 (1): 115

    PubMed  CAS  Google Scholar 

  34. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003; 49: 105–11

    Article  Google Scholar 

  35. Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006; 29 (1): 49–66

    Article  PubMed  CAS  Google Scholar 

  36. Sanchez Carazo JL, Santos LM, Martinez VO. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006; 29 (8): 675–85

    Article  Google Scholar 

  37. Lebwohl MG. Use of etanercept in the dermatology setting: a review. Am J Clin Dermatol 2005; 6 (1): 49–59

    Article  PubMed  Google Scholar 

  38. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17 (5): 401–8

    Article  PubMed  Google Scholar 

  39. Lebwohl M, Gottlieb A, Wallis W. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis [poster]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA)

    Google Scholar 

  40. Weinblatt ME, Genovese MC, Moreland LW. Safety and efficacy of up to 9 years of etanercept therapy in North American patients with rheumatoid arthritis [poster]. 65th Annual Meeting of the American Academy of Dermatology; 2007 Feb 2-6; Washington, DC

    Google Scholar 

  41. Tobin AM, Kirby B. TNF-alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Biodrugs 2005; 19 (1): 47–57

    Article  PubMed  CAS  Google Scholar 

  42. Zeltser R, Valle L, Tanck C. Clinical, histological and inmunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor Fc fusion protein. Arch Dermatol Oct 4-8; 2001; 137 (7): 93–9

    Google Scholar 

  43. European Medicine Agency (EMEA). Summary of product characteristics: Enbrel® [online]. Available from URL: http://www.emea.eu.int [Accessed 2007 Jan 20

  44. Klareskog L, Moreland LM, Cohen SB. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy [abstract no. 150]. Arthritis Rheum 2001; 44 Suppl. 44: 77

    Google Scholar 

  45. Sociedad Espänola de Reumatología. Spanish registry for adverse events of biological therapies in rheumatic diseases [online].Available from URL: http://biobadaser.ser.es [Accessed 2007 Jan 20

  46. Slifman NR, Gershon SK, Lee JH. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003 Feb; 48 (2): 319–24

    Article  PubMed  CAS  Google Scholar 

  47. Phillips K, Husni ME, Karlson EW. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002 Feb; 47 (1): 17–21

    Article  PubMed  CAS  Google Scholar 

  48. Keystone EC. Safety of biological therapies: an update. J Rheumatol 2005; 32 Suppl. 74: 8–12

    Google Scholar 

  49. Ekstrom K, Hjalgrim H, Brandt L. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48: 963–70

    Article  PubMed  Google Scholar 

  50. Gelfand JM, Berlin J, Van Voorhees A. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425–9

    Article  PubMed  Google Scholar 

  51. Brown SL, Greene MH, Gershon SK. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–8

    Article  PubMed  CAS  Google Scholar 

  52. Gottlieb AB, Leonardi CL, Goffe BS. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): 92–100

    Article  Google Scholar 

  53. Fryrear 2nd RS, Wiggins AK, Sangueza O. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy [letter]. J Am Acad Dermatol 2004; 51 (6): 1026

    Article  PubMed  Google Scholar 

  54. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Eng J Med 1991; 325: 467–72

    Article  CAS  Google Scholar 

  55. TNF neutralization in MS: results of a randomized placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53 (3): 457–65

    Google Scholar 

  56. Wong VK, Lebwohl MG. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist. Expert Opin Biol Ther 2005 Nov; 5 (11): 1505–13

    Article  PubMed  CAS  Google Scholar 

  57. Weinberg JM, Buchholz R, Scheinfeld N. Evidence-based review of biologic therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab, and alefacept. Adv Studies Med 2005; 5 (4): 195–206

    Google Scholar 

  58. Kwon HJ, Cote TR, Cuffe MS. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138 (10): 807–11

    PubMed  Google Scholar 

  59. Shakoor N, Michalska M, Harris CA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002 Feb 16; 359 (9306): 579–80

    Article  PubMed  CAS  Google Scholar 

  60. Bleumink GS, ter Borg EJ, Ramselaar CG. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001 Nov; 40 (11): 1317–9

    Article  PubMed  CAS  Google Scholar 

  61. Cairns AP, Duncan MK, Hinder AE. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002 Nov; 61 (11): 1031–2

    Article  PubMed  CAS  Google Scholar 

  62. De Rycke L, Baeten D, Kruithof E. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005 Jul; 52 (7): 2192–201

    Article  PubMed  Google Scholar 

  63. Hawrot AC, Metry DW, Theos AJ. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 2006 Jan-Feb 28; 23 (1): 67–71

    Article  PubMed  Google Scholar 

  64. Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis [letter]. J Am Acad Dermatol 2006 Mar; 54 (3 Suppl. 2): 126–8

    Article  Google Scholar 

  65. Militello G, Xia A, Stevens SR. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol 2006 Sep; 55 (3): 517–9

    Article  PubMed  Google Scholar 

  66. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004 Oct; 51 (4): 580–4

    Article  PubMed  Google Scholar 

  67. Allen EJ, Hurley Y, Leonardi C. Etanercept therapy in psoriasis patients with hepatitis C [poster]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LO)

    Google Scholar 

  68. Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005 Mar; 42 (3): 315–22

    CAS  Google Scholar 

  69. Aboulafia DM, Bundow D, Wilske K. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000 Oct; 75 (10): 1093–8

    Article  PubMed  CAS  Google Scholar 

  70. Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 2006 Jun; 45 (6): 689–92

    Article  PubMed  CAS  Google Scholar 

  71. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002 Jan; 146 (1): 118–21

    Article  PubMed  CAS  Google Scholar 

  72. Ortiz A, Yamauchi PS. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Skinmed 2006 Nov-Dec; 5 (6): 285–8

    Article  PubMed  Google Scholar 

  73. Moore A, Wright E, Ostroswki L. Etanercept and narrowband UVB combination therapy for plaque-type psoriasis shortens onset of action in both adults and children [poster]. 64th Annual Meeting of the American Academy of Dermatology; 2006 Mar 3-7; San Francisco (CA)

    Google Scholar 

  74. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004 Oct; 22 (4): 449–59

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr Romero-Maté received honoraria from Wyeth for the preparation of this review. The other authors have no conflicts of interest that are directly relevant to the content of this review.

The authors would like to thank Wyeth for providing assistance in locating some bibliographic material used in the preparation of this review.

The authors wish to thank José Manuel Moreno, Wolters Kluwer Health | Adis, for his assistance in the translation of the manuscript.

Author information

Authors and Affiliations

  1. Service of Dermatology, Fuenlabrada Hospital, Camino del Molino 2, CP: 28942, Fuenlabrada, Madrid, Spain

    Alberto Romero-Maté, Carmen García-Donoso & Susana Córdoba-Guijarro

Authors
  1. Alberto Romero-Maté
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen García-Donoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susana Córdoba-Guijarro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Romero-Maté.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romero-Maté, A., García-Donoso, C. & Córdoba-Guijarro, S. Efficacy and Safety of Etanercept in Psoriasis/Psoriatic Arthritis. AM J Clin Dermatol 8, 143–155 (2007). https://doi.org/10.2165/00128071-200708030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200708030-00002

Keywords

Search

Navigation